Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 6
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy

  • Holderfield, Matthew
  • Lee, Bianca J.
  • Jiang, Jingjing
  • Tomlinson, Aidan
  • Seamon, Kyle J.
  • Mira, Alessia
  • Patrucco, Enrico
  • Goodhart, Grace
  • Dilly, Julien
  • Gindin, Yevgeniy
  • Dinglasan, Nuntana
  • Wang, Yingyun
  • Lai, Lick Pui
  • Cai, Shurui
  • Jiang, Lingyan
  • Nasholm, Nicole
  • Shifrin, Nataliya
  • Blaj, Cristina
  • Shah, Harshit
  • Evans, James W.
  • Montazer, Nilufar
  • Lai, Oliver
  • Shi, Jade
  • Ahler, Ethan
  • Quintana, Elsa
  • Chang, Stephanie
  • Salvador, Anthony
  • Marquez, Abby
  • Cregg, Jim
  • Liu, Yang
  • Milin, Anthony
  • Chen, Anqi
  • Ziv, Tamar Bar
  • Parsons, Dylan
  • Knox, John E.
  • Klomp, Jennifer E.
  • Roth, Jennifer
  • Rees, Matthew
  • Ronan, Melissa
  • Cuevas-Navarro, Antonio
  • Hu, Feng
  • Lito, Piro
  • Santamaria, David
  • Aguirre, Andrew J.
  • Waters, Andrew M.
  • Der, Channing J.
  • Ambrogio, Chiara
  • Wang, Zhengping
  • Gill, Adrian L.
  • Koltun, Elena S.
  • Smith, Jacqueline A. M.
  • Wildes, David
  • Singh, Mallika
RAS oncogenes (collectively NRAS, HRAS and especially KRAS) are among the most frequently mutated genes in cancer, with common driver mutations occurring at codons 12, 13 and 611. Small molecule inhibitors of the KRAS(G12C) oncoprotein have demonstrated clinical efficacy in patients with multiple cancer types and have led to regulatory approvals for the treatment of non-small cell lung cancer2,3. Nevertheless, KRASG12C mutations account for only around 15% of KRAS-mutated cancers4,5, and there are no approved KRAS inhibitors for the majority of patients with tumours containing other common KRAS mutations. Here we describe RMC-7977, a reversible, tri-complex RAS inhibitor with broad-spectrum activity for the active state of both mutant and wild-type KRAS, NRAS and HRAS variants (a RAS(ON) multi-selective inhibitor). Preclinically, RMC-7977 demonstrated potent activity against RAS-addicted tumours carrying various RAS genotypes, particularly against cancer models with KRAS codon 12 mutations (KRASG12X). Treatment with RMC-7977 led to tumour regression and was well tolerated in diverse RAS-addicted preclinical cancer models. Additionally, RMC-7977 inhibited the growth of KRASG12C cancer models that are resistant to KRAS(G12C) inhibitors owing to restoration of RAS pathway signalling. Thus, RAS(ON) multi-selective inhibitors can target multiple oncogenic and wild-type RAS isoforms and have the potential to treat a wide range of RAS-addicted cancers with high unmet clinical need. A related RAS(ON) multi-selective inhibitor, RMC-6236, is currently under clinical evaluation in patients with KRAS-mutant solid tumours (ClinicalTrials.gov identifier: NCT05379985)., J.E. Klomp is funded by National Cancer Institute grants T32CA009156, F32CA239328 and K99CA276700, and American Cancer Society grant PF-20-069. P.L. is supported in part by the NIH/NCI (1R01CA23074501, 1R01CA23026701A1 and 1R01CA279264-01), The Pew Charitable Trusts, the Damon Runyon Cancer Research Foundation, and the Pershing Square Sohn Cancer Research Alliance. P.L. is also supported by the Josie Robertson Investigator Program and the Support Grant-Core Grant program (P30 CA008748) at Memorial Sloan Kettering Cancer Center. D.S. is funded by AECC Excellence Program 2022 (EPAEC222641CICS). A.J.A. has research funding from Bristol Myers Squibb, Deerfield, Eli Lilly, Mirati Therapeutics, Novartis, Novo Ventures, Revolution Medicines and Syros Pharmaceuticals. A.M.W. was supported by a grant from the NCI (K22CA276632-01). C.J.D. has received research funding support from Deciphera Pharmaceuticals, Mirati Therapeutics, Reactive Biosciences, Revolution Medicines, and SpringWorks Therapeutics, the National Cancer Institute (P50CA257911 and R35CA232113), Department of Defense (W81XWH2110692), and Pancreatic Cancer Action Network (22-WG-DERB). C.A. is funded by grants from the Giovanni Armenise–Harvard Foundation, the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation programme (grant agreement no. 101001288) and AIRC under IG 2021–ID. 25737 project., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Novel RAF-directed approaches to overcome current clinical limits and block the RAS/RAF node

  • Scardaci, Rossella
  • Berlinska, Ewa
  • Scaparone, Pietro
  • Vietti Michelina, Sandra
  • Garbo, Edoardo
  • Novello, Silvia
  • Santamaria, David
  • Ambrogio, Chiara
Mutations in the RAS–RAF–MEK–ERK pathway are frequent alterations in cancer and RASopathies, and while RAS oncogene activation alone affects 19% of all patients and accounts for approximately 3.4 million new cases every year, less frequent alterations in the cascade's downstream effectors are also involved in cancer etiology. RAS proteins initiate the signaling cascade by promoting the dimerization of RAF kinases, which can act as oncoproteins as well: BRAFV600E is the most common oncogenic driver, mutated in the 8% of all malignancies. Research in this field led to the development of drugs that target the BRAFV600-like mutations (Class I), which are now utilized in clinics, but cause paradoxical activation of the pathway and resistance development. Furthermore, they are ineffective against non-BRAFV600E malignancies that dimerize and could be either RTK/RAS independent or dependent (Class II and III, respectively), which are still lacking an effective treatment. This review discusses the recent advances in anti-RAF therapies, including paradox breakers, dimer-inhibitors, immunotherapies, and other novel approaches, critically evaluating their efficacy in overcoming the therapeutic limitations, and their putative role in blocking the RAS pathway., Giovanni Armenise–Harvard Foundation European Research Council (ERC). Grant Number: 101001288 Associazione Italiana per la Ricerca sul Cancro. Grant Number: 25737, Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Experimental variables determine the outcome of RAS-RAS interactions

  • Zhou, Zhiwei
  • Nguyen, Tra Ly
  • Li, Xingxiao
  • Poujol, Christel
  • Berlinska, Ewa
  • Vietti Michelina, Sandra
  • Kapp, Jonas N.
  • Plückthun, Andreas
  • Winslow, Monte M.
  • Ambrogio, Chiara
  • Shan, Yibing
  • Santamaria, David
  • Westover, Kenneth D.
RAS clustering at the cell membrane is critical to activate signaling in cells, but whether this clustering is mediated exclusively by its c-terminal hypervariable region, receives contributions from the G-domain of RAS, and/or is influenced by secondary effectors has been intensely debated. Reports that G-domain mutations do not modulate RAS-RAS interactions have led some to question the validity of previous experiments that indicate the G-domain plays a role in RAS clustering/interactions. Here we reconcile these findings by clarifying the impact of experimental variables, such as protein expression levels, cellular context, RAS zygosity, and secondary effector interactions on RAS clustering. Lack of control over these variables impacts the results using G-domain mutations across various assay systems and can lead to unsound conclusions., This work was supported by CPRIT RP220145 and NIH R01CA244341 to KDW, NIH R01-CA230025 to MMW, Antidote Health Foundation for Cure of Cancer to YS, the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation programme (grant agreement No. [101001288]) and AIRC under IG 2021 - ID. 25737 project (to C.A.), the Ministerio de Ciencia e Innovación (Retos PID2020–116824RB-I00) and Institut National du Cancer (INCA_13911) to DS, and Swiss Cancer Research foundation to AP (KFS 4147–02–2017 and KFS-5290–02–2021-R)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

RAS-ON inhibition overcomes clinical resistance to KRAS G12C-OFF covalent blockade

  • Nokin, Marie-Julie
  • Mira, Alessia
  • Patrucco, Enrico
  • Ricciuti, Biagio
  • Cousin, Sophie
  • Soubeyran, Isabelle
  • San José, Sonia
  • Peirone, Serena
  • Caizzi, Livia
  • Vietti Michelina, Sandra
  • Bourdon, Aurelien
  • Wang, Xinan
  • Daniel Alvarez-Villanueva, Daniel
  • Martínez-Iniesta, María
  • Vidal, August
  • Rodrigues Teixeira, Telmo
  • García-Macías, Carmen
  • Awad, Mark M.
  • Nadal, Ernest
  • Villanueva, Alberto
  • Italiano, Antoine
  • Cereda, Matteo
  • Santamaria, David
  • Ambrogio, Chiara
Selective KRASG12C inhibitors have been developed to covalently lock the oncogene in the inactive GDP-bound state. Two of these molecules, sotorasib and adagrasib, are approved for the treatment of adult patients with KRASG12C-mutated previously treated advanced non-small cell lung cancer. Drug treatment imposes selective pressures leading to the outgrowth of drug-resistant variants. Mass sequencing from patients’ biopsies identified a number of acquired KRAS mutations -both in cis and in trans- in resistant tumors. We demonstrate here that disease progression in vivo can also occur due to adaptive mechanisms and increased KRAS-GTP loading. Using the preclinical tool tri-complex KRASG12C-selective covalent inhibitor, RMC-4998 (also known as RM-029), that targets the active GTP-bound (ON) state of the oncogene, we provide a proof-of-concept that the clinical stage KRASG12C(ON) inhibitor RMC-6291 alone or in combination with KRASG12C(OFF) drugs can be an alternative potential therapeutic strategy to circumvent resistance due to increased KRAS-GTP loading., This work was funded by grants from Institut National du Cancer (grant No. INCA_13911), SIRIC-BRIO (Bordeaux Recherche Intégrée en Cancérologie, INCa convention 2018-006 & INSERM convention 18CI05500), the French government in the framework of the Investments for the Future program IdEx-Université de Bordeaux, Ministerio de Ciencia e Innovación (PID2020-116824RB-I00) and Scientific Foundation of the Spanish Association Against Cancer (EPAEC222641CICS and PRYGN222960SANT) (to D.S.), the Giovanni Armenise–Harvard Foundation, the Italian Ministry of University and Research (FARE-R207ENY9KZ), the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation program (grant agreement No. [101001288]), AIRC under IG 2021—ID. 25737 project and Revolution Medicines under a sponsored research agreement (to C.A.), Instituto de Salud Carlos III (grant PI21/00789) (co-funded by European Regional Development Fund, ERDF, a way to build Europe) (to E.N.) and two grants from the Spanish Ministry of Economy and Competitiveness - Instituto de Salud Carlos III FEDER (PI21/00789 and FIS PI22-00548), Generalitat de Catalunya 2021SGR00184 (to E.N. and A.V., respectively). M.J.N. was supported by a bourse d’excellence de la Fédération Wallonie-Bruxelles (WBI) and a postdoctoral fellowship from Foundation ARC pour la recherche contre le cancer. B.R. was supported by the Barbara Gomez Endowed Advanced Program in Thoracic Oncology. D.A.-V. held a PFIS predoctoral fellowship (FI20/00130) from Instituto de Salud Carlos III. M.C. is supported by AIRC under MFAG 2017—ID. 20566 and BRIDGE 2023—ID. 28739 projects and the Compagnia di San Paolo Foundation. C.A. is supported by the Zanon di Valgiurata family through Justus s.s., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

SOS1 inhibitor BI-3406 shows in vivo antitumor activity akin to genetic ablation and synergizes with a KRASG12D inhibitor in KRAS LUAD

  • Baltanás, Fernando C.
  • Kramer Drauberg, Maximilian
  • García-Navas, Rósula
  • Patrucco, Enrico
  • Petrini, Ettore
  • Arnhof, Heribert
  • Olarte-San Juan, Andrea
  • Rodríguez-Ramos, Pablo
  • Borrajo, Javier
  • Calzada, Nuria
  • Castellano, Esther
  • Mair, Barbara
  • Kostyrko, Kaja
  • Hofmann, Marco H.
  • Ambrogio, Chiara
  • Santos de Dios, Eugenio
We evaluated the in vivo therapeutic efficacy and tolerability of BI-3406-mediated pharmacological inhibition of SOS1 in comparison to genetic ablation of this universal Ras-GEF in various KRAS-dependent experimental tumor settings. Contrary to the rapid lethality caused by SOS1 genetic ablation in SOS2KO mice, SOS1 pharmacological inhibition by its specific inhibitor BI-3406 did not significantly affect animal weight/viability nor cause noteworthy systemic toxicity. Allograft assays using different KRASmut cell lines showed that treatment with BI-3406 impaired RAS activation and RAS downstream signaling and decreased tumor burden and disease progression as a result of both tumor-intrinsic and -extrinsic therapeutic effects of the drug. Consistent with prior genetic evidence and the KRASmut allografts assays in immunocompromised mice, our analyses using an in vivo model of KRASG12D-driven lung adenocarcinoma (LUAD) in immunocompetent mice showed that single, systemic BI-3406 treatment impaired tumor growth and downmodulated protumorigenic components of the tumor microenvironment comparably to SOS1 genetic ablation or to treatment with the specific KRASG12D inhibitor MRTX1133. Furthermore, markedly stronger, synergistic antitumor effects were observed upon concomitant treatment with BI-3406 and MRTX1133 in the same in vivo LUAD mouse model. Our data confirm SOS1 as an actionable therapy target in RAS-dependent cancers and suggest that BI-3406 treatment may yield clinical benefit both as monotherapy or as a potential combination partner for multiple RAS-targeting strategies., Instituto de Salud Carlos III-Ministerio de Ciencia e Innovación grant FIS PI19/00934 (E.S.) Junta de Castilla y León grant SA264P18-UIC 076 (E.S.) Fundación Ramón Areces grant CIVP19A5942 (E.S.) Instituto de Salud Carlos III -CIBERONC grant CB16/12/00352 (E.S.) Asociación Española Contra el Cancer Excellence program STOP RAS CANCERS grant EPAEC222641CICS (E.S.) MICIU/AEI/10.13039/501100011033/ grant PID2022-136409OB-I00 (F.C.B.) MICIU/AEI/10.13039/501100011033/ and European Union NextGenerationEU/PRTR grant CNS2022-135292 (F.C.B.) Fundación Solorzano-Barruso grant FS/32-2020 (F.C.B.) Fundación Eugenio Rodríguez Pascual (F.C.B.) Asociación Inés de Pablo Llorens-Grupo GETTHI (F.C.B.) Ministerio de Ciencia e Innovación grant RTI2018-099161-A-I00 (E.C.) The Giovanni Armenise–Harvard Foundation (C.A.) The European Research Council under the European Union’s Horizon 2020 research and innovation programme grant 101001288 (C.A.) MIUR FARE grant R207ENY9KZ (C.A.) AIRC under IG 2021 - ID. 25737 (C.A.) This research was cofinanced by FEDER funds. These CIC groups are supported by the Programa de Apoyo a Planes Estratégicos de Investigación de Estructuras de Investigación de Excelencia of Castilla y León autonomous government (CLC-2017-01). M.K.-D. was supported by Fondazione Umberto Veronesi. C.A. is supported by the Zanon di Valgiurata family through Justus s.s. The research project was selected and funded for 2 y by Boehringer Ingelheim in a Molecule for Collaboration (M4C) call submitted to the opn.me platform (www.opnme.com) We thank Astrid Jeschko for her contribution performing the Pharmacokinetic studies, Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Oncogenic mutant KRAS inhibition through oxidation at cysteine 118

  • Kramer-Drauberg, Maximilian
  • Petrini, Ettore
  • Mira, Alessia
  • Patrucco, Enrico
  • Scardaci, Rossella
  • Savinelli, Ilenia
  • Wang, Haiyun
  • Qiao, Keying
  • Carrà, Giovanna
  • Nokin, Marie-Julie
  • Zhou, Zhiwei
  • Westover, Kenneth D.
  • Santamaria, David
  • Porporato, Paolo
  • Ambrogio, Chiara
Specific reactive oxygen species activate the GTPase Kirsten rat sarcoma virus (KRAS) by reacting with cysteine 118 (C118), leading to an electron transfer between C118 and nucleoside guanosine diphosphate (GDP), which causes the release of GDP. Here, we have mimicked permanent oxidation of human KRAS at C118 by replacing C118 with aspartic acid (C118D) in KRAS to show that oncogenic mutant KRAS is selectively inhibited via oxidation at C118, both in vitro and in vivo. Moreover, the combined treatment of hydrogen-peroxide-producing pro-oxidant paraquat and nitric-oxide-producing inhibitor N(ω)-nitro-l-arginine methyl ester selectively inhibits human mutant KRAS activity by inducing oxidization at C118. Our study shows for the first time the vulnerability of human mutant KRAS to oxidation, thereby paving the way to explore oxidation-based anti-KRAS treatments in humans., This work was funded by the Giovanni Armenise–Harvard Foundation, the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation programme (grant agreement No. [101001288]) and AIRC under IG 2021 – ID. 25737 project (to CA). MK-D was supported by Fondazione Umberto Veronesi. CA is supported by the Zanon di Valgiurata family through Justus s.s., Peer reviewed